Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 110 people in total — 56 in the Durezol group and 54 in the Pred Forte group. The trial was comparing two eye drop medicines used to treat inflammation inside the eye (a condition involving swelling and irritation in the front chamber of the eye). The main thing being measured was the change in the level of inflammatory cells visible in the front part of the eye, assessed by a doctor using a special lamp and graded on a scale from 0 (very few or no cells) to 4 (a very high number of cells). By the end of the study, 47 people in the Durezol group and 39 in the Pred Forte group had completed the trial. The reported data shows that at the start of the study, both groups had an average cell grade of 2.6 out of 4. By day 14 — the main measurement point — the Durezol group's average score had dropped by 2.2 points, while the Pred Forte group's average score had dropped by 2.0 points. The reported data also shows changes measured at earlier time points, with both groups showing a gradual reduction in their scores across the visits. For a separate measure — the proportion of participants whose cell count reached zero — the reported figures at day 14 were 73.9% in the Durezol group and 48.9% in the Pred Forte group. A measure combining near-zero cell counts and no visible protein leakage showed 82.6% for Durezol and 76.6% for Pred Forte at day 14. Changes in protein leakage (called "flare") were also tracked, and both groups showed similar reductions across all time points, reaching an average drop of around 2.0 points by the final visits. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 24677110) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a specific type of eye inflammation (called anterior uveitis) that originates from within the body, affecting at least one eye.
- There is a significant level of inflammation visible in the front part of at least one eye, measured by the number of cells and amount of haziness seen during an eye exam.
- You are 2 years old or older on the day you give consent to join the study.
- If you are a female who could become pregnant, you must have a negative pregnancy test on the first day of the study.
- Other eligibility requirements set by the study may also apply (confirm with trial site).
Who may not be able to join:
- Your anterior uveitis was diagnosed more than 2 weeks before enrolling in the study.
- You have inflammation in other parts of your eye beyond the front section (such as the middle, back, or the whole eye).
- You have used any steroid or anti-inflammatory eye drops in the eye being studied within 7 days before starting the study drug.
- You have a history of glaucoma or significantly raised eye pressure (21 mmHg or higher) in either eye.
- You have a history of steroid eye drops previously causing your eye pressure to rise.
- You have any active infection (viral, bacterial, or fungal) affecting the surface of either eye.
- You have a scratch or open sore on the clear surface of either eye (the cornea).
- You are currently pregnant or breastfeeding.
- Other reasons set by the study may also prevent you from joining (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.